Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reimportation Bill From Dorgan/Snowe Includes User Fees To Fund Oversight

Executive Summary

A reimportation bill reintroduced by Sens. Byron Dorgan (D-N.D.) and Olympia Snowe (R-Maine) includes user fees for importers and foreign exporters to fund FDA's safety oversight
Advertisement

Related Content

Drug Importation Often Driven By Personal, Not Pricing, Concerns, FDA Finds
Rx Importation Legislation Debate Begins Anew, But Battle Lines Are Familiar
Rx Import Bill Endorsed By Kessler; Beats “Uncontrolled Risk”
Free Trade Agreements Not Useful Against Price Controls – Commerce Official
Medicare Drug Spending Expected To Surpass Total Current Rx Sales By 2014
Medicare Drug Spending Expected To Surpass Total Current Rx Sales By 2014
Rx Import Debate Launches In Senate With Introduction Of Four Bills
Canada-Only Import Plan “Feasible,” HHS Says: Savings Would Be “Modest”
Senate Drug Import Bill Would Require Notice Of Manufacturing Changes
Senate Drug Import Bill Would Require Notice Of Manufacturing Changes

Topics

Advertisement
UsernamePublicRestriction

Register

PS045380

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel